A breast cancer survivor organized a seminar at the Oncology department of the Lagos University Teaching Hospital in the presence of the dean and consultants of the department to give a testimonial on how Sorghum bicolor supplement Jobelyn saved her life.
the Lagos University Teaching Hospital (LUTH), Idi Araba, Lagos. They spoke at the seminar tagged: ‘Let’s kill it! organised by a Non-Governmental Organisation (NGO), Atinuke Cancer Foundation. Despite that some of the patients looked frail, were on the wheelchair, they were bound by one thing – cancer, which they are determined to eradicate.
Sitting under the well-decorated tent in front of the Oncology and Radiology Department of LUTH, some of the survivors praised an herbal supplement – Jobelyn – for providing succour for them.
A survivor, Mrs Atinuke Lawal, the NGO’s founder, said Jobelyn stabilises cancer patients’ haematocrit which is why it is recommended for treating and managing cancer.
She said: “I can recommend the drug to anybody living with cancer or a survivor. I put up this event, and dedicated a day out of the three days, to ensure that people receiving treatment, have adequate information about what worked for me, and others. I intend to let them know this message across our target audience, especially in Lagos, through the media -TV, Radio, newspaper and the new media – that cancer can be overcome. I will extend the NGO’s frontiers to the rest of the world.” See Full report at: https://thenationonlineng.net/hope-cancer-patients/
Sorghum bicolor supplement Jobelyn is listed in the drug dictionary of the National Cancer Institute and described as being rich in Polyphenols and phenolic acids with the potential for antioxidant, anti-inflammatory, immunomodulating and chemopreventive capabilities. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sorghum-bicolor-supplemen
The details of the concepts of Jobelyn concepts were also published at: https://ncim.nci.nih.gov/ncimbrowser/pages/concept_details.jsf?dictionary=NCI%20Metathesaurus&code=CL454073&type=all# The testimony could also be viewed on YouTube at: https://youtu.be/RTk5XT83FbU
Commentaires